Latest Articles about ABT

Covidien Provides 2013 Outlook - Analyst Blog

Zacks Equity Research — Mon, 06 May 2013 21:22:46 Z

Covidien plc ( COV ) has revealed its guidance for fiscal 2013 after adjusting for the spin-off of the Pharmaceutical business, which is expected to take place at the end of third quarter

Earnings Beat for ABAX, Sluggish Overall - Analyst Blog

Zacks Equity Research — Sat, 27 Apr 2013 00:00:01 Z

Provider of portable blood analysis systems for human and veterinary patient-care, Abaxis Inc. ( ABAX ) reported fourth-quarter fiscal 2013 earnings per share ("EPS") of 30 cents,

Abbott - Epizyme Collaborate - Analyst Blog

Zacks Equity Research — Wed, 24 Apr 2013 02:10:27 Z

Abbott Laboratories ( ABT ) recently announced a strategic deal with Epizyme, Inc. for the development of a molecular companion diagnostic test for use with EPZ-5676. EPZ-5676 is being

New Product from Abbott Labs - Analyst Blog

Zacks Equity Research — Tue, 23 Apr 2013 02:09:40 Z

Abbott Laboratories ( ABT ) recently announced that the company has gained approval from the US Food and Drug Administration (FDA) for its TECNIS Toric 1-Piece intraocular lens (IOL). The

Abbott Labs Recalls Glucose Meter - Analyst Blog

Zacks Equity Research — Sat, 20 Apr 2013 01:12:50 Z

Abbott Laboratories ( ABT ) recently announced that the company is initiating a voluntary recall of its FreeStyle InsuLinx Blood Glucose Meters in the US. Abbott Labs decided to recall the

S&P Likes The Biggest Dividend ETF

ETF Professor — Fri, 19 Apr 2013 20:39:47 Z

Dividend stocks and ETFs have been all the rage this year, underscoring the risk off nature of the broader market's rally . Low volatility, high dividend sectors such as utilities health

Abbott Launches Automated Solution - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 02:11:15 Z

Abbott Laboratories ( ABT ) recently announced that the company has launched ACCELERATOR a3600 - its next-generation track system to increase efficiency in laboratories. A laboratory

Company News for April 18, 2013 - Corporate Summary

Zacks Equity Research — Thu, 18 Apr 2013 18:36:01 Z

• Intel Corporation (NASDAQ: INTC ) reported first quarter earnings per share of $0.40, missing the Zacks Consensus Estimate of $0.42 • CSX

Abbott Reports In-Line 1Q Earnings - Analyst Blog

Zacks Equity Research — Wed, 17 Apr 2013 21:13:30 Z

Abbott Laboratories ( ABT ) reported first quarter 2013 earnings of 42 cents per share, in line with the Zacks Consensus Estimate and 5.0% above the year-ago earnings. Including one-time

Gold Is Still on the Fritz

Minyanville Staff — Wed, 17 Apr 2013 00:45:00 Z

Gold (NYSEARCA:GLD), the major story of the past two trading days, had a very erratic session today. The yellow metal traded in an intraday range between $1,321 and $1,402 and had multiple $30

Pre-Market Earnings Report for April 17, 2013 : BAC, ABT, PNC, BK, ASML, MAT, DOV, STJ, DGX, TXT, HBAN, FCFS

NASDAQ.com News — Wed, 17 Apr 2013 00:00:04 Z

The following companies are expected to report earnings prior to market open on 04/17/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Bank of America

Guru Stocks at 52-Week Highs

GuruFocus — Mon, 15 Apr 2013 20:06:37 Z

According to GuruFocus' list of 52-week highs , these Guru stocks have reached their 52-week highs. Abbott Laboratories ( ABT ) Reached the 52-Week High of $37.13 The prices of Abbott

Abbott's Heart FailureTest in Europe - Analyst Blog

Zacks Equity Research — Fri, 12 Apr 2013 03:08:19 Z

Abbott Labs ( ABT ) recently announced that the company obtained CE Marking (Conformite Europeenne) for its ARCHITECT Galectin-3 assay test. We note that CE mark is mandatory confirmation

Pharma & Biotech Stock Outlook - Apr 2013 - Industry Outlook

Zacks Equity Research — Thu, 04 Apr 2013 11:04:01 Z

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck's ( MRK )

Pharma & Biotech Stock Outlook - Apr 2013 - Zacks Analyst Interviews

Zacks Equity Research — Thu, 04 Apr 2013 11:04:01 Z

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck's ( MRK )